In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Working in the in vivo cell therapy space, Johnson discusses the injection of a manufactured vector into a patient to create the CAR-T cells directly inside the body of the patient, without the need for chemotherapy treatment beforehand – hence such hope for in vivo cell therapy’s potential. Targeting both T-cells and NK-cells, Johnson notes that this is a distinguishing factor of the work Interius does.
On the CAR-T space generally, Comstock and Johnson explore its evolution and how these products can be made faster, better, and cheaper – including the democratisation of these therapies, and the accessibility gains this means for patients.
